Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA   US9216591084

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/26/2014 08/27/2014 08/28/2014 08/29/2014 09/02/2014 Date
12.95(c) 12.89(c) 12.36(c) 12.94(c) 13.24 Last
353 849 205 025 548 007 254 916 197 295 Volume
+0.86% -0.46% -4.11% +4.69% +2.32% Change
More quotes
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes Fanapt and Tasimelteon. The Fanapt product is a compound for the treatment of schizophrenia,... 
Surperformance© rating of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More about the company
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 46,5 M
EBIT 2014 -65,8 M
Net income 2014 -76,1 M
Debt 2014 -
Yield 2014 -
Sales 2015 89,5 M
EBIT 2015 -58,2 M
Net income 2015 -62,9 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 9,43x
Capi. / Sales 2015 4,90x
Capitalization 438 M
More Financials
Latest news on VANDA PHARMACEUTICALS INC.
08/14DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
08/08 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
08/07 VANDA PHARMACEUTICALS : Results of Operations and Financial Condition, Financial..
08/07 VANDA PHARMACEUTICALS : Reports Second Quarter 2014 Results
07/30 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
07/23 VANDA PHARMACEUTICALS : Assigned Patent
07/17 VANDA PHARMACEUTICALS : to Announce Second Quarter 2014 Financial Results on Aug..
07/17 VANDA PHARMACEUTICALS : Other Events (form 8-K)
06/16 VANDA PHARMACEUTICALS : Other Events (form 8-K)
06/12 VANDA PHARMACEUTICALS : European Medicines Agency Accepts HETLIOZ™ tasimel..
06/10 VANDA PHARMACEUTICALS : Other Events (form 8-K)
06/04 WEDNESDAY'S ETF MOVERS : Xbi, gxc
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
Vanda Pharmaceuticals Inc. : Income Statement Evolution
More Financials
EPS Revisions
Vanda Pharmaceuticals Inc. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF